ATG16L1 and inflammatory bowel disease: To date, multiple protective effects of ATG16L1 in IBD have been discovered, including enhancing Th1/Th17 response,30 facilitating host‐bacteria interactions in myeloid cells31 and particularly preventing PC abnormality and death.